Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease
Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease
复制标题
DOI：
10.1001/archotol.131.12.1097
复制
发表时间：
2005-12-01
影响因子：
--
通讯作者：
Raia, V
中科院分区：
文献类型：
--
作者：
Cimmino, M;Nardone, M;Raia, V
目的：确定鼻吸入阿法链核酸酶对囊性纤维化和鼻部症状患者的益处。设计：双盲安慰剂对照试验。单位：那不勒斯大学坎帕尼亚囊性纤维化区域中心。“病人：共24例囊性纤维化和慢性鼻窦炎患者。干预措施：患者在3年期间接受了鼻窦手术，并在手术后1个月开始接受每日一次剂量的阿法链核酸酶（15 mg）或低渗盐水溶液（5 mL），持续12个月。主要结果测量：主要结果是鼻相关症状和鼻内窥镜外观;次要结果是1秒用力呼气量、鼻计算机断层扫描结果和糖精清除试验结果。结果：手术后1个月，每种治疗方法的所有结果均明显改善（P
Objective: To determine the benefit of nasally inhaled dornase alfa in patients with cystic fibrosis and nasal symptoms.Design: Double-blind placebo-controlled trial. Setting: Cystic Fibrosis Regional Center of Campania at the University of Naples "Federico II."Patients: A total of 24 patients with cystic fibrosis and chronic sinusitis.Interventions: Patients underwent sinonasal surgery during a 3-year period and received once-daily doses of either dornase alfa (15 mg) or hypotonic saline solution (5 mL) beginning 1 month after surgery and for a 12-month period.Main Outcome Measures: Primary outcomes were nasal-related symptoms and nasal endoscopic appearance; secondary outcomes were forced expiratory volume in 1 second, nasal computed tomography findings, and saccharine clearance test results. Patients were evaluated before and after treatment.Results: After surgery, all outcomes were significantly improved for each treatment at 1 month (P